Value
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.6 |
| P/S | 8.1 |
| EV/EBITDA | 6.2 |
| Fwd P/E | 9.1 |
| PEG | 4.8 |
| Analyst target | 6.0 |
- ▸Forward P/E: 11.4x
- ▸PEG: 1.74
- ▸Attractively valued
ZTS · Why this verdict
Why Zoetis (ZTS) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.6/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Zoetis is a high-quality animal health business with 68% return on equity, 28% net margins, and a 3-for-4 earnings beat streak — but an extraordinary put-to-call ratio of 18.50, a confirmed death-cross technical pattern, and heavy concentration in companion animal products (70%) create a profile where the long-term quality case is strong but the near-term setup is unusually risky.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Zoetis achieves a 68% return on equity, 28% net margins, and a quality score of 8.3 — ranking in the top decile of its peer group on quality — with a Piotroski F-Score of 8/9, reflecting the durable pricing power of branded animal health products. Quality breakdown | Return on equity remains above 50% and net margins stay above 22% over the next 4 quarters, confirming the quality advantage is structural. | →Stable |
| CounterFree cash flow covers only 67% of net income — a quality warning — suggesting that reported margins may not fully translate into distributable cash due to working capital or capital spending requirements. | ||
Companion animal products account for 70% of revenue, representing a high product-concentration risk — any regulatory setback, pricing pressure from generics, or shift in veterinary spending patterns would disproportionately impact the business. Bear case | Livestock or international product revenue grows to represent more than 35% of total revenue within 18 months, reducing companion animal concentration below 65%. | ↑Improving |
| CounterCompanion animal spending has shown exceptional resilience through economic downturns as pet ownership and veterinary care spending have structurally increased; the concentration reflects a highly attractive end market. | ||
Zoetis has a put-to-call options ratio of 18.50 — one of the highest readings observable in large-cap healthcare — indicating an extraordinary level of downside protection being purchased relative to upside calls, which historically signals institutional concern about a specific near-term risk event. Risk breakdown | Put-to-call ratio falls below 5.0 within 3 months, declining by more than 70% from the current extreme 18.50 level, as the options market concern resolves. | ↑Improving |
| CounterAn extreme put-to-call ratio can reflect concentrated options hedging by a small number of large institutional holders rather than broad market bearishness; the signal may overstate the genuine directional view. | ||
The stock is in a confirmed death-cross pattern with the 200-day moving average declining at -7.7% per 30 days and the 52-week position at its lowest point, despite a recovering MACD and RSI at 49 — the technical structure is inconsistent and the downtrend has not yet reversed. Momentum breakdown | The 200-day moving average slope improves to flat or positive within 6 months, and the stock price rises above the 200-day average for at least 10 consecutive trading days. | Tripped↑Improving |
| CounterThe 40% analyst upside to $112.13 from the current $79.95 suggests the market has materially overshot to the downside; an improving MACD at the current low RSI may signal the death-cross exhaustion point. | ||
Zoetis achieves a 68% return on equity, 28% net margins, and a quality score of 8.3 — ranking in the top decile of its peer group on quality — with a Piotroski F-Score of 8/9, reflecting the durable pricing power of branded animal health products.
→StableQuality breakdown
- Expectation
- Return on equity remains above 50% and net margins stay above 22% over the next 4 quarters, confirming the quality advantage is structural.
CounterFree cash flow covers only 67% of net income — a quality warning — suggesting that reported margins may not fully translate into distributable cash due to working capital or capital spending requirements.
Companion animal products account for 70% of revenue, representing a high product-concentration risk — any regulatory setback, pricing pressure from generics, or shift in veterinary spending patterns would disproportionately impact the business.
↑ImprovingBear case
- Expectation
- Livestock or international product revenue grows to represent more than 35% of total revenue within 18 months, reducing companion animal concentration below 65%.
CounterCompanion animal spending has shown exceptional resilience through economic downturns as pet ownership and veterinary care spending have structurally increased; the concentration reflects a highly attractive end market.
Zoetis has a put-to-call options ratio of 18.50 — one of the highest readings observable in large-cap healthcare — indicating an extraordinary level of downside protection being purchased relative to upside calls, which historically signals institutional concern about a specific near-term risk event.
↑ImprovingRisk breakdown
- Expectation
- Put-to-call ratio falls below 5.0 within 3 months, declining by more than 70% from the current extreme 18.50 level, as the options market concern resolves.
CounterAn extreme put-to-call ratio can reflect concentrated options hedging by a small number of large institutional holders rather than broad market bearishness; the signal may overstate the genuine directional view.
The stock is in a confirmed death-cross pattern with the 200-day moving average declining at -7.7% per 30 days and the 52-week position at its lowest point, despite a recovering MACD and RSI at 49 — the technical structure is inconsistent and the downtrend has not yet reversed.
Tripped↑ImprovingMomentum breakdown
- Expectation
- The 200-day moving average slope improves to flat or positive within 6 months, and the stock price rises above the 200-day average for at least 10 consecutive trading days.
CounterThe 40% analyst upside to $112.13 from the current $79.95 suggests the market has materially overshot to the downside; an improving MACD at the current low RSI may signal the death-cross exhaustion point.
Per-dimension breakdown
Quality
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.9 |
| FCF quality | 5.8 |
| Moat | 5.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 7.8 |
- ▸Excellent ROE: 65%
- ▸Strong margins: 28%
- ▸Earnings quality warning: 76% FCF/NI
- ▸Rule of 40: 21 (fail)
Growth
2.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.5 |
| EPS growth | 2.2 |
- ▸Declining revenue: -0%
Momentum
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -6.9%/30d — confirmed downtrend
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 7.2 |
| Price target | 8.3 |
- ▸Analyst upside: 26%
Insider
5.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.7 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.3 |
| quality rank | 9.0 |
| growth rank | 2.1 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
0.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 1.0 |
| 52w position | 0.1 |
Risk (lower is worse)
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.5 |
| days to cover | 6.6 |
| volatility | 6.9 |
| put call | 8.4 |
| implied vol | 4.2 |
| max pain risk | 7.0 |
| beta | 8.6 |
| debt equity | 2.1 |
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 3.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 3.2 |
| dividend safety | 9.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
V9 Gate blocked: R/R 1.1x at spot < 1.5 minimum. Wait for improvement.
Engine technical detail
verdict_path:
L4:PATH_A_DEEP_VALUE->V9:POOR_ASYMMETRY|ENTRY_STICKY:WITHIN_BANDPassed (8)
- MOMENTUM:5.8>=5.5
- INSIDER:OK
- DEATH_CROSS:QUALITY_MOMENTUM_EXEMPT
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:22d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
- SECTOR_CONCENTRATION_CAP:sector=Healthcare:1/10:self_excluded
Failed (1)
- ASYMMETRY:1.1<1.5@spot
Warning (2)
- DEATH_CROSS:quality=8.2>=7.5+momentum=5.8>=5.0 exempted
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.11
Upside
+9.6%
Downside
8.6%
Sizing output
STARTER
SetupRecovery — Death cross but MACD improving, RSI 70
EdgeCatalyst-Driven — Earnings in 22d with 3/4 beat streak
SuitabilitySpeculative — Drawdown -50% (>40% off 52w high)
Investment implication
The STRONG_BUY_WAIT verdict reflects the ASYMMETRY gate's 1.1<1.5@spot outcome against Quality at 8.2 and asymmetric R:R of 1.11.
The strongest dimensions are Quality at 8.2, Value at 7.0, and Sentiment at 6.8; the weakest are Technical at 0.6, Growth at 2.4, and Peer rank at 4.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 1.11 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Put Call Ratio Warning
Trip ifPut-to-call ratio rises above 25.0, exceeding the current extreme 18.50 level, indicating options market concern is intensifying.
- P2Top Decile Quality Metrics
Trip ifReturn on equity falls below 40% for 2 consecutive quarters, declining more than 40% from the current 68% level.
- P3Companion Animal Concentration 70pct
Trip ifCompanion animal revenue declines by more than 10% year-over-year for 2 consecutive quarters.
- P4Death Cross Steep Ma DeclineTripped
Trip ifPrice drops below $72, declining more than 10% below the current $79.95, while the 200-day MA slope remains below -5% per 30 days.